|
|
|
Volumn 5, Issue 8, 2002, Pages 792-796
|
|
Lower Urinary Tract Disorders - Ray Fuller Symposium Physiology, Pharmacology and Therapeutic Approaches 6-7 July 2002, San Francisco, CA, USA
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE;
3 [2 (4 CHLOROPHENYLTHIO)PHENYL] N (4 DIMETHYLAMINOBUTYL)ACRYLAMIDE;
4 [3,4 DIOXO 2 (1,2,2 TRIMETHYLPROPYLAMINO) 1 CYCLOBUTENYLAMINO] 3 ETHYLBENZONITRILE;
A 119637;
A 278637;
A 344905;
ADENOSINE TRIPHOSPHATE;
ALFUZOSIN;
ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT;
APOMORPHINE;
AZD 0947;
CAPSAICIN;
DARIFENACIN;
DOPAMINE RECEPTOR STIMULATING AGENT;
DOXAZOSIN;
DUTASTERIDE;
FINASTERIDE;
GUANYLATE CYCLASE;
MUSCARINIC RECEPTOR BLOCKING AGENT;
N (4 BENZOYLPHENYL) 3,3,3 TRIFLUORO 2 HYDROXY 2 METHYLPROPIONAMIDE;
NEUROKININ 1 RECEPTOR ANTAGONIST;
OXYTOCIN;
PHOSPHODIESTERASE INHIBITOR;
PHOSPHODIESTERASE V INHIBITOR;
PINACIDIL;
POTASSIUM CHANNEL;
POTASSIUM CHANNEL STIMULATING AGENT;
PURINE P2X RECEPTOR;
PURINE P2X RECEPTOR ANTAGONIST;
PURINERGIC RECEPTOR BLOCKING AGENT;
RESINIFERATOXIN;
SILDENAFIL;
SSR 240600;
STEROID 5ALPHA REDUCTASE INHIBITOR;
TADALAFIL;
TAMSULOSIN;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
URINARY TRACT AGENT;
VANILLOID RECEPTOR AGONIST;
VARDENAFIL;
BLADDER FUNCTION;
CENTRAL NERVOUS SYSTEM FUNCTION;
CLINICAL TRIAL;
CONFERENCE PAPER;
DISEASE COURSE;
DRUG ABSORPTION;
DRUG BLOOD LEVEL;
DRUG DOSE REGIMEN;
DRUG EFFECT;
DRUG MECHANISM;
DRUG STRUCTURE;
DRUG TISSUE LEVEL;
DRUG TOLERABILITY;
ERECTILE DYSFUNCTION;
GENE THERAPY;
GENETIC TRANSFECTION;
HEALTH CARE ORGANIZATION;
HUMAN;
LONG TERM CARE;
NAUSEA;
NONHUMAN;
OVERACTIVE BLADDER;
PERIPHERAL NERVOUS SYSTEM FUNCTION;
PROSTATE;
PROSTATE HYPERTROPHY;
QUANTITATIVE ANALYSIS;
SEXUAL DYSFUNCTION;
SYMPOSIUM;
SYMPTOMATOLOGY;
URETHRA DISEASE;
URINARY TRACT DISEASE;
UROGENITAL TRACT DISEASE;
XEROSTOMIA;
|
|
EID: 1642472928
PISSN: 13697056
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
|
Times cited : (2)
|
|
References (0)
|
